Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Overview Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development Incyte Corp Inflection Biosciences Ltd Jasco Pharmaceuticals LLC Novartis AG Sanofi SARomics Biostructures AB Tolero Pharmaceuticals Inc Yakult Honsha Co Ltd Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drug Profiles Gene Therapy to Activate PIM1 for Myocardial Infarction - Drug Profile Product Description Mechanism Of Action R&D Progress IBL-100 - Drug Profile Product Description Mechanism Of Action R&D Progress INCB-53914 - Drug Profile Product Description Mechanism Of Action R&D Progress LGB-321 - Drug Profile Product Description Mechanism Of Action R&D Progress SBX-1501 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CSNK2 and PIM1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit PIM1 and PIM3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Pim Kinase for Pancreatic Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Pim-1 for Prostate Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PIM1 and PIM2 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SMI-4a - Drug Profile Product Description Mechanism Of Action R&D Progress TP-3654 - Drug Profile Product Description Mechanism Of Action R&D Progress Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Dormant Products Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Discontinued Products Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Product Development Milestones Featured News & Press Releases Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013 Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2018 Number of Products under Development by Therapy Areas, H2 2018 Number of Products under Development by Indication, H2 2018 Number of Products under Development by Companies, H2 2018 Products under Development by Companies, H2 2018 Products under Development by Companies, H2 2018 (Contd..1), H2 2018 Number of Products under Investigation by Universities/Institutes, H2 2018 Products under Investigation by Universities/Institutes, H2 2018 Number of Products by Stage and Mechanism of Actions, H2 2018 Number of Products by Stage and Route of Administration, H2 2018 Number of Products by Stage and Molecule Type, H2 2018 Pipeline by Incyte Corp, H2 2018 Pipeline by Inflection Biosciences Ltd, H2 2018 Pipeline by Jasco Pharmaceuticals LLC, H2 2018 Pipeline by Novartis AG, H2 2018 Pipeline by Sanofi, H2 2018 Pipeline by SARomics Biostructures AB, H2 2018 Pipeline by Tolero Pharmaceuticals Inc, H2 2018 Pipeline by Yakult Honsha Co Ltd, H2 2018 Dormant Products, H2 2018 Dormant Products, H2 2018 (Contd..1), H2 2018 Discontinued Products, H2 2018List of Figures Number of Products under Development by Stage of Development, H2 2018 Number of Products under Development by Therapy Areas, H2 2018 Number of Products under Development by Top 10 Indications, H2 2018 Number of Products by Mechanism of Actions, H2 2018 Number of Products by Stage and Mechanism of Actions, H2 2018 Number of Products by Stage and Route of Administration, H2 2018 Number of Products by Molecule Types, H2 2018 Number of Products by Stage and Molecule Types, H2 2018

Incyte Corp Inflection Biosciences Ltd Jasco Pharmaceuticals LLC Novartis AG Sanofi SARomics Biostructures AB Tolero Pharmaceuticals Inc Yakult Honsha Co Ltd